The Institute's radiopharmaceutical production site has successfully been recertified according to the strict GMP standards of the Eurasian Economic Union, once again confirming the impeccable quality and reliability of its products. This achievement underlines the high level of production and guarantees that each preparation meets the striсtest international requirements.
Currently, the INP produces the key radiopharmaceuticals that play a vital role in the diagnosis and treatment of cancer, that include Fluorodeoxyglucose F-18, Sodium Pertechnitate Tc-99 and Sodium Iodide I-131. These radiopharmaceuticals are required for accurate diagnosis and effective therapy, helping the patients to recover.
